Hemophilia
Conditions
Interventions
Matacizumab observation group:None
Sponsors
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Hainan Hospital (Boao Research Hospital, Hainan)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with hemophilia A or hemophilia B without an inhibitor; 2. Patients who have received at least 1 month or at least 4 doses of matacizumab treatment in Boao Pilot Area of Hainan; 3. Adolescent patients (12 years =18 years); 4. Clinicians prescribe matasicumab for patients with the indications approved for matasicumab in Boao Pilot Area of Hainan according to the actual conditions of patients; 5. Informed consent was obtained from the participant or a legally authorized representative or guardian of the participant who was able to sign an informed consent form before enrollment;
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PPQ(Patient Preference Questionnaire); | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient Global Impression of Change Scale score; | — |
Countries
China
Contacts
Public ContactXuefeng Wang
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed